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ABSTRACT
Occupational exposures to ionising radiation mainly occur
at low-dose rates and may accumulate effective doses of
up to several hundred milligray.
The objective of the present study is to evaluate the
evidence of cancer risks from such low-dose-rate,
moderate-dose (LDRMD) exposures.
Our literature search for primary epidemiological studies
on cancer incidence and mortality risks from LDRMD
exposures included publications from 2002 to 2007, and
an update of the UK National Registry for Radiation
Workers study. For each (LDRMD) study we calculated
the risk for the same types of cancer among the atomic
bomb survivors with the same gender proportion and
matched quantities for dose, mean age attained and
mean age at exposure. A combined estimator of the ratio
of the excess relative risk per dose from the LDRMD study
to the corresponding value for the atomic bomb survivors
was 1.21 (90% CI 0.51 to 1.90).
The present analysis does not confirm that the cancer risk
per dose for LDRMD exposures is lower than for the
atomic bomb survivors. This result challenges the cancer
risk values currently assumed for occupational exposures.
Occupational and medical diagnostic exposures to
ionising radiation are mainly due to Roentgen rays
and gamma rays, which belong to so-called low-
linear energy transfer (LET) radiation. The expo-
sures may accumulate over a lifetime to doses of
the order of 100 mGy. For example, in the 15-
countries collaborative study on radiation workers
in the nuclear industry, about 10% of the 407 000
study members received external doses exceeding
50 mGy, while only 0.1% received doses exceeding
500 mGy.
1 Exposures with doses in the range of
50–500 mGy are considered here to be moderate in
comparison with the high-dose groups of the
atomic bomb survivors from Hiroshima and
Nagasaki.
Within an hour, which is the timescale for
cellular repair processes, doses from occupational
and medical diagnostic exposures do not generally
exceed the order of 10 mGy. Thus, these exposures
occur at low-dose rate.
It follows that estimates of health risks, in
particular of cancer risks, related low-dose-rate,
moderate-dose (LDRMD) exposures are of central
importance for practical radiation protection.
Current estimates of cancer risks from LDRMD
exposures are mainly based on risk coefficients
derived from the Japanese atomic bomb survivors,
that is, from persons with acute, high-dose
exposures, which are then combined with a ‘‘dose
and dose-rate effectiveness factor’’ (DDREF).
23
Values for DDREF have mainly been deduced from
experiments with laboratory animals and from
radiobiological measurements. Specifically, the
International Commission on Radiological
Protection (ICRP) derived estimates of the excess
cancer risk after low-dose exposures and after
exposures with higher doses but low-dose rates by
reducing the corresponding risk value for the
atomic bomb survivors by a DDREF of 2.0.
2 The
BEIR VII Committee of the US National Research
Council used a DDREF of 1.5.
3
During the past few years, a number of
epidemiological studies have been published, which
provide major information on cancer risk after
LDRMD exposures. The statistical power of each
of these studies is not strong because of the
relatively low risks of the doses involved.
Therefore, the present study focuses on studies of
larger groups of cancers. More specifically, studies
of all cancer, all cancer excluding leukaemia, all
solid cancer and all solid cancer excluding bone
cancer have been included.
In the present paper, values of the excess relative
risk (ERR) per dose in LDRMD studies of cancer
risks from exposures to low-LET radiation are
compared with those calculated for the atomic
bomb survivors for the same grouping of cancer
types, gender distribution, average age at exposure,
average age attained and dose quantity. A com-
bined estimator of the resulting risk ratios is
calculated. Based on this risk estimator, cancer
lifetime risks are assessed.
What this paper adds
c Occupational exposures to ionising radiation
occur normally at low-dose rate and may sum
up to moderate doses in the order of 100 mGy.
c Limits of occupational exposures are based on
the assumption that cancer risk factors are
lower than for the atomic bomb survivors by a
factor of two.
c Twelve recent epidemiological studies on cancer
after low-dose-rate, moderate-dose exposures
were included in this analysis of cancer risks
related to such exposures.
c The studies provide evidence that cancer risk
factors for occupational exposures are not lower
than for atomic bomb survivors.
c The new evidence for cancer risks should be
taken into account in optimisation procedures
for the use of radionuclides and ionising
radiation at the work place and in medicine.
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include a value of zero, which would correspond to an infinite
value of the DDREF. In order to avoid resulting instabilities of
the calculations, the inverse DDREF value, Q, that is, the ratio
of the ERR-per-dose value in the LDRMD study to that for the
atomic bomb survivors, is calculated here.
METHODS
Literature search
A systematic literature search for primary epidemiological
studies was conducted in the PubMed database in January
2008, covering the period January 2002 to December 2007. The
search terms ‘‘radiation’’ and ‘‘cancer’’ were combined with
alternatives of the terms ‘‘occupation’’, ‘‘work’’, ‘‘personnel’’,
and ‘‘environmental’’ or ‘‘emergency’’. A number of exclusion
terms were specified to limit the findings to ionising radiation
effects in the occupational, environmental or emergency setting.
An initial selection of 714 papers was identified. The PubMed
search was augmented by a manual search for references, by
which a paper on Chernobyl emergency and clean-up workers
4
and a paper on Oak Ridge National Laboratory (ORNL)
workers
5 were identified. Further, stimulated by a suggestion
of a reviewer, a recent study on the UK National Registry for
Radiation Workers
6 was included in the analysis, because of its
outstanding importance. Results without inclusion of this study
are also reported below.
The initial selection was then restricted to cohort and case-
control studies and epidemiological reviews, which left 123
papers. Further eliminations were made of studies on exposures
to alpha radiation (because most of the occupational exposures
are due to external radiation), focused on children or individual
cancer sites, or without dosimetry. Further, nine publications
were not included in our analysis mainly because relative risk
estimates and their standard deviations could not be derived,
7–11
because there were many cohort members with high expo-
sures,
12 13 because no data of the Life Span Study (LSS) were
available for the corresponding group of cancers among the
atomic bomb survivors
14 or the required information on age at
exposure and age at risk were not obtained.
15
If a study contained results for different cancer outcomes,
then the outcome closest to ‘‘solid cancer’’ was chosen.
Especially, inclusion of leukaemia was avoided as far as possible
because of differences in height of risk and in shape of dose
response, if compared with solid cancer.
Concerning the 15-countries collaborative study of cancer risk
among radiation workers in the nuclear industry,
16 the present
analysis includes only results, which are not based on the
Canadian data, because problems with the application of the
Canadian data within the 15-countries study have been
reported (Norman Gentner, personal communication, 2008).
ERR per dose for atomic bomb survivors
The publicly available atomic bomb survivor datasets for cancer
mortality from 1950 to 2000 (DS02can.dat) and cancer
incidence from 1958 to 1998 (lssinci07.csv) from the Radiation
Effects Research Foundation (http://www.rerf.or.jp) were used
to calculate ERR-per-dose values for acute exposures. Only
survivors with doses below 4 Gy of shielded kerma were used in
the risk analysis.
The atomic bomb survivor data for the cancer categories used
in an LDRMD study, i were fitted with a model including an
explicit ERR-per-dose parameter, blssi, a male fraction, fi, an age
at exposure, ei and an age-attained, ai:
l(di, s, e, a)=l0(s, e, a)[ 1 + blssi di ri(s, e, a)] (1)
with
ri(s, e, a)=hi(s) exp[ai (e 2 ei) + vi ln (a/ai)] (2)
and
hi(s)=1 + his fi,i fs = female
(3)
hi(s)=1 2 his (12 fi), if s = male
Here l is the total mortality/incidence rate, l0 the baseline
rate, di the dose (see below), s gender, e the age at exposure, a
the age at risk and ai, vi, and his are parameters. For ei, the
average age at start of follow-up in the LDRMD study was
chosen as a surrogate for average age at exposure. The modelling
of age-at-exposure and age-attained dependences in equation (2)
is the way the age parameters are treated in recent A-bomb
papers, for example, by Preston et al.
17
We based the risk calculations for the atomic bomb survivors
c on the dose to that organ as it was used in the corresponding
LDRMD study, if the study was based on an organ dose
c the skin dose, if the LDRMD study was based on film badge
or TLD readings.
Neutron doses were weighed by a factor of 10.
The Poisson regressions were performed with the programme
AMFIT of the software package EPICURE (HiroSoft
International Corp., Seattle, Washington, USA).
Ratio of ERR-per-dose values
The ratio of the ERR-per-dose value, bldrmdi, in an LDRMD
study i and the corresponding value for the atomic bomb
survivors was calculated as:
qi = bldrmdi/blssi. (4)
Normal distributions were assumed for bldrmdi and blssi with
average values corresponding to the best estimates given in the
publications (for bldrmdi) or obtained in the Poisson regression
(for blssi). Standard deviations of the single estimates were
estimated by dividing the width of their respective confidence
interval by twice the appropriate quantile of the normal
distribution. Percentiles and the variance Vi of qi were calculated
from 1000 samples from each distribution generated with the
Monte Carlo software package Crystal Ball (Decisioneering,
Denver, Colorado, USA).
Combined estimator of the risk ratio
A combined estimator of the ratio of the ERR-per-dose values
for LDRMD and acute exposures was obtained by the inverse
variance method for calculating a weighted average of the ratios
for the single LDRMD studies.
where n is the number of LDRMD studies considered.
The ratio Q was calculated separately for studies of cancer
mortality and for studies of cancer incidence. Some of the
LDRMD mortality studies had part of the data in common. In
order to avoid a double counting of such mortality data, two
analyses including only independent studies were performed. In
the first analysis, LDRMD studies with the larger number of
cancer mortality cases were used. In the second analysis, instead
of these, LDRMD studies with the smaller number of cases were
included. Out of the three analyses (two for cancer mortality
and one for incidence) the combined risk estimator with the
narrowest uncertainty range (the ratio of the upper and the
lower boundary of the 90% confidence interval) was defined to
Review
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excluding single studies from the main analysis. Study hetero-
geneity was assessed by calculating Cochran’s Q statistic and
the corresponding p value.
Lifetime risks
The BEIR VII committee performed a probabilistic calculation of
the lifetime-solid-cancer mortality and incidence risks per dose for
low-dose-rate exposures to external radiation according to:
lrBEIRVII = lrlss/DDREFBEIRVII (6)
where lrlss is the lifetime risk per dose for acute, high-dose
exposures as derived for most cancer sites from the incidence
data of the atomic bomb survivors from Hiroshima and
Nagasaki, transferred to the American population.
3
DDREFBEIRVII has a mode of 1.5 and a 95% CI of 1.1 to 2.3.
Lifetime-solid-cancer mortality and incidence risks per dose
for LDRMD exposures have been calculated here as:
lrldrmd = lrBEIRVII DDREFBEIRVII Q (7)
In the calculation, lrBEIRVII and DDREFBEIRVII were assumed
to be negatively correlated with a correlation coefficient of
20.5. In order to check the impact of this subjective choice,
limiting calculations were also performed for values of the
correlation coefficients of 0 and 21.
The ICRP has defined the detriment-adjusted nominal risk
coefficient as a weighted sum of lifetime risks per dose for fatal
and non-fatal cancer, severe heritable effects, and length of life
lost. The coefficient is calculated by:
dICRP = dlss/DDREFICRP (8)
where dlss is the detriment-adjusted nominal risk coefficient for
cancer after acute, high-dose exposures as derived mainly from
the incidence data of the atomic bomb survivors.
2 DDREFICRP
has the value of 2.
Taking account of the cancer risk per dose in LDRMD
epidemiological studies, a detriment-adjusted nominal risk
coefficient for cancer was assessed here according to:
dldrmd = dICRP DDREFICRP Q (9)
RESULTS
Studies of low-dose-rate, moderate-dose exposures
All 12 studies selected for the analysis were cohort studies. The
nine mortality studies (table 1) and three incidence studies
(table 2) included seven studies on radiation workers,
5 6 16 18–20
three studies on emergency and clean-up workers after the
Chernobyl accident
42 12 2 and two studies on the residents of
villages located along the banks of the Techa River.
23 24 Although
a number of Chernobyl liquidators have obtained high-dose-rate
exposures, the studies are included here, because the vast
majority had only low-dose-rate exposures. None of the 12
studies include a considerable number of cohort members with
cumulative exposures exceeding a few hundred milligray.
The best estimates of the ERR were positive in all studies (in
one study it was 0.0). In seven of the 12 studies the excess
cancer risk was significantly related to the radiation exposure.
Table 1 List of cancer mortality studies, which were included in the analysis
No Reference, country Population
Follow-up, cancer
cases Type of exposure Cancer outcomes
ERR per dose, bldrmd (Gy)
21, best
estimate and 90% CI
1 Boice 2006, USA
18 Workers at Rocketdyne 21999, 3066 External and internal All cancer excluding
leukaemia
0.0 (21.9 to 2.4)*
2 Cardis 2007, 14
countries{
16
Radiation workers in
nuclear industry
Variable, 6119 External All cancer excluding
leukaemia
0.6 (20.1 to 1.4)
3 Ivanov 2001, Russia{
21 Chernobyl clean-up
workers
1991–1998, 515 External Neoplasms ICD-9 140–239 2.1 (1.3 to 2.9)*
4 Ivanov 2006, Russia
4 Chernobyl clean-up
workers
1992–2002, 651 External Solid cancer 1.5 (0.2 to 2.9)*
5 Krestinina 2005, Russia
24 Techa River residents 21999, 1842 External and internal Solid cancer except bone
cancer
0.9 (0.2 to 1.7)*
6 Muirhead 2009, UK
6 Radiation workers 22001, 6959 External Malignant neoplasms
excluding leukaemia
0.3 (0.02 to 0.6)
7 Stayner 2007, USA
5 ORNL workers 21984, 225 External All cancer excluding
leukaemia
4.8 (0.4 to 13.3)1
8 Telle-Lamberton 2007,
France"
19
French nuclear workers 1968–1994, 721 External All cancer excluding
leukaemia
1.5 (20.5 to 4.0)
9 Wing 2005, USA
20 Hanford workers 21994, 2265 External and internal All cancer 0.3 (20.3 to 1.0)
ERR, excess relative risk; ORNL, Oak Ridge National Laboratory.
*95% confidence interval.
{Canadian data excluded from 15-countries study.
{Summarised by Ivanov et al
25 in 2007, and therefore included in our analysis.
1After correction for dose uncertainties. The result without this correction is 5.4 (0.5 to 12.6) Gy
21.
"Results for ‘‘all cancer excluding leukaemia’’ were supplied by personal communication with Telle-Lamberton (2008).
Table 2 List of cancer incidence studies, which were included in the analysis
No Reference, country Population
Follow-up, cancer
cases Type of exposure Cancer outcomes
ERR per dose, bldrmd (Gy)
21, best
estimate and 90% CI
10 Ivanov 2004, Russia
22 Chernobyl clean-up
workers
1996–2001, 1370 External Solid cancer 0.3 (20.4 to 1.2)*
11 Krestinina 2007, Russia
23 Techa River residents 1956–2002, 1836 External and internal Solid cancer except bone
cancer
1.0 (0.3 to 1.9)*
12 Muirhead 2009, UK
6 Radiation workers 22001, 10 855 External Malignant neoplasms
excluding leukaemia
0.3 (0.04 to 0.5)
*95% confidence interval.
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The ERR-per-dose estimates for the atomic bomb survivors
matched by categories of cancer mortality, sex ratios, average
ages at exposure and average ages at risk of the LDRMD studies
vary by more than a factor of 2.5 (tables 3 and 4). The highest
estimate corresponds to the conditions in the cancer incidence
study of the Techa River residents: a value of 0.59 (95% CI 0.49
to 0.69) Gy
21 is obtained for relatively young average age at first
exposure (25 years) and a large fraction of females (0.57). Also,
the risk estimation is related to the dose in a relatively well-
shielded organ (stomach). The lowest estimate corresponds to a
mortality study of Chernobyl liquidators: a value of 0.23 (95%
CI 0.11 to 0.34) Gy
21 is obtained for all solid cancer and a high
male fraction (100% males). Further, the risk is related to the
relatively high dose in skin.
Comparison of ERR-per-dose values for different types of exposure
Generally, the uncertainties of the ERR estimates in the
LDRMD studies are much larger than the corresponding
estimates for atomic bomb survivors (figs 1 and 2). In six of
the 12 LDRMD studies, the best estimate of the ERR per dose is
larger than that for the atomic bomb survivors by more than a
factor of 1.5, in five studies it is comparable, and only in one
study it is smaller by more than a factor of 1.5.
The risk ratio, q, is significantly larger than 1.0 for the two
mortality studies of Chernobyl clean-up workers.
42 1 In the
remaining 10 LDRMD studies, the cancer-risk-per-dose values
are compatible with those from the study of the atomic bomb
survivors.
Combined estimator of the risk ratio
No statistical heterogeneity was detected between the esti-
mated ratios, qi, included in each of the three analyses (table 5).
It should be noted, however, that the power of the test is not
strong in view of the small number of studies included. The
uncertainty range of the combined estimator for the larger
mortality studies and for the incidence studies had the same
width. The analysis of the larger mortality studies was chosen
as the main analysis because it includes more studies.
The main analysis includes seven cancer mortality studies,
five of nuclear workers,
561 8 – 2 0one of Chernobyl emergency and
clean-up workers
21 and one of Techa River residents.
24 A risk
ratio, Q, of 1.21 (90% CI 0.51 to 1.90) is obtained. The best
estimate for the smaller mortality studies is larger; the
difference is, however, not significant (p=0.16). The combined
estimator for the incidence studies is relatively close to the
result of the main analysis.
Leaving out one of the studies changed the best estimate of Q
in the main analysis at most by 26%. The lowest risk ratio with
a value of 0.96 (90% CI 0.12 to 1.80) was obtained when the
study of the Techa River residents was excluded. The highest
risk ratio with a value of 1.44 (90% CI 0.48 to 2.41) was
obtained when the study of the UK radiation workers was
excluded.
Lifetime risks
Based on assessments of BEIR VII for lifetime cancer risks after
acute exposures and on the results of the present analysis
(equation 7), a number of about 14 (90% CI 6 to 31) or 24 (90%
CI 9 to 49) excess solid cancer cases among 1000 males or
females, respectively, is obtained for LDRMD gamma-ray
exposures with a dose of 100 mGy. It is further estimated that
there would be about seven (90% CI 3 to 15) or 11 (90% CI 4 to
23) excess fatalities from solid cancer among males or females,
respectively.
If lrBEIRVII and DDREFBEIRVII were assumed to be not or
completely anti-correlated, then the best estimates of the
Table 3 Datasets, parameters and risk per dose for the atomic bomb survivors corresponding to the low-dose-rate, moderate-dose studies of cancer
mortality in table 1, and the risk ratios, qi
No Population Male fraction
Average age
at start of
follow-up
Average age
at end of
follow-up Dose quantity
ERR per dose (Gy
21) in LSS,
blss, best estimate and 90% CI
Risk ratio, q, best estimate
and 90% CI
1 Workers at Rocketdyne 0.92 31 56 Skin dose 0.26 (0.16 to 0.35)* 0.00 (27.25 to 7.33)
2 Radiation workers in nuclear
industry
0.90 31 46 Colon dose 0.49 (0.30 to 0.67) 1.19 (20.34 to 3.12)
3 Chernobyl clean-up workers{ 1.00 35 47 Skin dose 0.47 (0.29 to 0.65)* 4.49 (2.79 to 7.17)
4 Chernobyl clean-up workers 1.00 35 50 Skin dose 0.23 (0.11 to 0.34)* 6.66 (1.67 to 14.7)
5 Techa River residents{ 0.40 28 63 Stomach dose 0.54 (0.42 to 0.65)* 1.71 (0.52 to 3.04)
6 UK radiation workers 0.90 29 52 Skin dose 0.30 (0.21 to 0.39) 0.91 (0.01 to 2.01)
7 ORNL workers 1.00 30 57 Skin dose 0.25 (0.16 to 0.33) 19.6 (26.38 to 51.3)
8 French nuclear workers 0.79 31 49 Skin dose 0.33 (0.23 to 0.43) 4.59 (22.34 to 12.6)
9 Hanford workers 0.76 31 55 Skin dose 0.41 (0.33 to 0.49) 0.73 (20.87 to 2.35)
ORNL, Oak Ridge National Laboratory.
*95% confidence interval.
{Calculations performed for all cancer, because out of 515 neoplasms (ICD-9 140–239) there were only three non-cancer cases (ICD-9 208–239).
{Calculations performed for all solid cancer, because mortality data with DS02 were not available for bone cancer.
Table 4 Datasets, parameters and risk per dose for the atomic bomb survivors corresponding to the low-dose-rate, moderate-dose studies of cancer
incidence in table 2, and the risk ratios, qi
No Population Male fraction
Average age
at start of
follow-up
Average age
at end of
follow-up Dose quantity
ERR per dose (Gy
21) for acute
exposure, blss, best estimate and
90% CI
Risk ratio, q, best estimate
and 90% CI
10 Chernobyl clean-up workers 1.00 35 49 Skin dose 0.33 (0.21 to 0.46)* 0.99 (21.10 to 3.25)
11 Techa River residents 0.43 25 65 Stomach dose 0.59 (0.49 to 0.69)* 1.70 (0.54 to 2.92)
12 UK radiation workers 0.90 29 52 Skin dose 0.37 (0.29 to 0.46) 0.71 (0.09 to 1.42)
*95% confidence interval.
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intervals are increased or decreased by about 30%, respectively.
The radiation protection system of the ICRP is based on the
effective dose. For whole body exposures with low-LET
radiation, the effective dose in the unit Sievert (Sv) is
numerically equal to the absorbed dose in the unit Gray (Gy)
as it was used by BEIR VII. Based on the assessment of the ICRP
for the detriment-adjusted nominal cancer risk coefficient for
acute exposures and on the result of the present analysis
(equation 9), an estimate of the detriment-adjusted nominal risk
coefficient for workers of about 10 (90% CI 4 to 16) 10
22 Sv
21 is
obtained for LDRMD exposures. Representing essentially a sum
of excess cancer fatalities and of weighted excess non-fatal
cancer cases, this value is slightly larger than the sex-averaged
result for the mortality risk as described above.
DISCUSSION
Strengths and limitations of the present study
It is the strength of the analysis to have extracted the following
common information from a number of recent epidemiological
studies of cancer after LDRMD exposures:
Figure 1 Excess relative risk per dose
for cancer mortality in nine studies of
low-dose-rate, moderate-dose exposures
(red symbols), as compared with acute,
high-dose exposures (atomic bomb
survivors of Hiroshima and Nagasaki)
(blue symbols). The error bars indicate
95% CIs for the studies of workers at
Rocketdyne, the Chernobyl emergency
workers and the Techa River residents,
and 90% CIs for all other studies.
Figure 2 Excess relative risk per dose
for cancer incidence in three studies of
low-dose-rate, moderate-dose exposures
(red symbols), as compared with acute,
high-dose exposures (atomic bomb
survivors of Hiroshima and Nagasaki)
(blue symbols). The error bars indicate
95% CIs for the Chernobyl emergency
workers and the Techa River residents,
and 90% CIs for the UK National Registry
for Radiation Workers.
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exposures to ionising radiation.
c There is no indication that the excess cancer risk per dose for
LDRMD exposures is smaller than for the atomic bomb
survivors.
c These results still hold if single studies are excluded from the
analysis.
Most of the studies included in the present analysis have
methodological limitations especially concerning dosimetry. It is
impossible to predict how improvements of dosimetry would or
will change the results of the single LDRMD studies. A Monte
Carlo simulation study incorporating uncertainty in the dose
parameters estimated for study of ORNL workers found very
little impact of these uncertainties on ERR-per-dose estimates.
5
Further, if future changes of the results of several LDRMD
studies do not go in the same direction (increasing or decreasing
the risk), then implications for the general results of the present
analyses are expected to be low, because
c the risk ratios in the three different analyses presented in
table 5 are quite consistent;
c the risk ratio of the main analysis is not strongly affected by
a single study.
Another severe limitation of the LDRMD studies is the non-
availability of data on risk factors other then radiation,
especially of smoking data. Such risk factors may confound
the results. Since, however, neither the LDRMD studies nor the
analyses of the atomic bomb survivors take such risk factors
into account, the risk ratios derived in the present paper may be
less affected by the missing information than the risk estimates
themselves.
A main limitation of the present analysis is the inclusion of
results for different exposed groups and different groups of
cancer types. Indeed, the relative risks among the atomic bomb
survivors matching the conditions of the LDRMD studies vary
by more than a factor of 2.5. There is no obvious way to avoid
this limitation because the available single studies and even the
large 15-countries pooled analysis do not have enough statistical
power to allow conclusions as drawn in the present paper.
However, the calculation of risk ratios for comparable condi-
tions (groups of cancer types, male fraction, age at exposure, age
attained, dose quantity used in the risk analysis, mortality or
incidence data) in the present paper and the determination of a
combined estimator for these ratios alleviate the problem with
heterogeneous study conditions and endpoints.
Another limitation is the fact that published risk estimates
were used instead of individual data from the included studies.
Access to individual data from some of the excluded studies is
possible via the Comprehensive Epidemiologic Data Resource
(http://cedr.lbl.gov/). However, for the current analyses such
extensive data acquisition and analysis could not be undertaken.
Finally, in the comparison of risks from protracted and acute
exposures, the definition of age at exposure is problematic. In
the present analysis, the average age at the start of follow-up
has been used in the comparison. An older effective age at
exposure would be more correct, but could not be estimated in
this study. Using an older effective age at exposure would result
in lower ERR-per-dose estimates for acute exposures and thus in
even higher qi values than obtained in the present analysis.
In summary, the value of the present study is a general
estimation of implications of published studies rather than a
quantitative risk evaluation.
Comparison with low-dose-rate, high-dose exposures
Two papers have been published in the past few years on large
cohort studies of solid cancer risk due to low-dose-rate, but
high-dose exposures.
One study included workers at the Mayak Production
Association in the Southern Urals, Russia, which produced
plutonium for the atomic weapons of the former Soviet
Union.
13 These workers were exposed to external radiation
and to plutonium which exposed mainly lungs, liver and bone.
A first analysis of the cancer mortality with regard to other
Table 5 Ratios of the excess relative risk per dose in low-dose-rate, moderate-dose studies and for the
atomic bomb survivors as calculated in three analyses (main analysis in bold)
Endpoint
Criterion to select
independent studies
Numbers of studies
included*
Risk ratio, Q, best estimate
and 90% CI
p Value for
heterogeneity
Mortality Larger number of cancer
cases
1, 4, 5, 6, 7, 8, 9 1.21 (0.51 to 1.90) 0.79
Mortality Smaller number of cancer
cases
1, 2, 3, 5 2.08 (1.16 to 3.01) 0.21
Incidence – 10, 11, 12 0.98 (0.41 to 1.54) 0.49
*Compare tables 1 and 2.
Figure 3 Ratio Q of excess relative risk-per-dose values for cancer
after low-dose-rate, moderate-dose exposures and after acute, high-dose
exposures as recommended by the International Commission on
Radiological Protection (ICRP),
2 used by BEIR VII (95% CI),
3 and derived
in the present analysis from epidemiological studies (epi-risk, 90% CI).
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was considerably lower than that for the atomic bomb
survivors. It may, however, be noted that leukaemia risks per
dose were quite comparable.
The second study included residents of northern Kazakhstan
who were exposed to the fallout and also to external radiation
from atomic bomb explosions performed at the nuclear
Semipalatinsk test site.
12 The best estimate of the excess relative
cancer mortality risk per dose was considerably higher than that
for the atomic bomb survivors.
In summary, these high-dose studies do not provide contra-
dictory evidence for the present evaluation of LDRMD exposure
studies.
Comparison with BEIR VII and ICRP recommendations
According to BEIR VII, cancer risk after LDRMD exposure is
expected tobe by a factor of 1.5, according tothe ICRP by a factor
of 2, smaller than among atomic bomb survivors. However, the
best estimates of the cancer risk in 11 of the 12 LDRMD studies
are larger than both expectations (tables 3 and 4).
Due to low statistical power most single studies are
consistent with the BEIR VII and ICRP recommendations: the
90% confidence ranges of 10 of the 12 risk ratios, qi, include the
value of 0.67, corresponding to the inverse DDREF value used by
BEIR VII; eight include the ICRP value of 0.5.
According to the main analysis in the present paper, the
combined estimator of the risk ratio, Q,i sc o m p a t i b l ew i t ht h e
DDREF used in BEIR VII, although the BEIR VII risk estimates are
in the lower range (fig 3). The risk value recommended by the
ICRP is smaller than the present result for LDRMD exposures.
This result is borderline significant on the 90% confidence level.
The ICRP and BEIR VII base their DDREFs mainly on
radiobiological results including animal data, which, in their
majority, suggest a characteristically low risk for low-dose-rate
exposures. It remains an open question as to why this
characteristic is apparently not reflected in the human
epidemiological data.
Implications
The recent epidemiological studies analysed here provide some
evidence that cancer risks associated with LDRMD exposures to
ionising radiation may be greater than those published by BEIR
VII and the ICRP.
The ICRP rationale for radiation protection is based on three
concepts: justification, dose limitation, and optimisation. The
results of the new epidemiological studies highlight the need for
justification of the use of radionuclides and ionising radiation in
medicine, industry and research. Derivation of dose limits for
radiation protection is a complex process including, for example,
comparisons of occupational exposures with exposures to
radiation from natural sources, or of radiation risks with other
occupational health and mortality risks. Compared with earlier
recommendations, the ICRP decided in 1991 to considerably
reduce the recommended limit on effective dose for occupa-
tional exposures to 20 mSv per year, averaged over 5 years
(100 mSv in 5 years).
26 Estimates of cancer risks related to
exposures with cumulated doses of 100 mSv have been given in
the Results section.
The ICRP has defined optimisation ‘‘as the source-related
process to keep the likelihood of incurring exposures…, the
number of people exposed, and the magnitude of individual
doses as low as reasonably achievable, taking economic and
societal factors into account’’.
2 The new epidemiological results
may influence optimisation procedures for future use of
radionuclides and ionising radiation.
Probability-of-causation calculations play an important role
in the adjudication of claims of compensations for cancer
diseases after occupational radiation exposures. The computer
code IREP made available by the US National Institute for
Occupational Safety and Health (http://www.niosh-irep.com)
is widely used for these calculations. The IREP includes a
DDREF, which lowers the probability of causation for low-dose-
rate exposures.
27 Use of such a factor in these calculations is
questioned by the new epidemiological studies. Indeed, in the
UK compensation scheme it is not assumed that low-dose
exposures result in a lower risk per dose than acute, high-dose
exposures.
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APPENDIX 1: RELATION OF WHOLE BODY DOSE AND SKIN
DOSE
The term ‘‘whole body dose’’, as used in a number of epidemiological studieso f
workers exposed to ionising radiation, relates to the dosimeter dose worn in front of
the trunk of the worker. Values for this dose quantity are not available for the atomic
bomb survivors. The main exposure of the atomic bomb survivors is due to Roentgen
rays or gamma rays in the energy range of 100 keV to a few MeV. In this Appendix an
organ is identified, for which dose values are available and which may servea sa
surrogate for the whole body dose among atomic bomb survivors.
Zankl published conversion coefficients for the whole body dose, or more specifically
for the personal dose equivalent, Hp(10), per air kerma free in air, Ka (in Sv Gy
21) for a
typical dosimeter position, for monoenergetic photons incident in various irradiation
geometries.
29 The ICRP published conversion coefficients of 15 organs in an
anthropomorphic phantom per kerma free in air for monoenergetic photons incident in
various irradiation geometries.
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We calculated the ratios of these two sets of conversion factors for two irradiation
geometries: parallel from the front (anterior-posterior) and parallel from all horizontal
directions (rotational invariant). For the photon energies and irradiation geometries of
interest, the conversion coefficients for skin were found to be similar to the conversion
coefficients for whole body dose: for both irradiation geometries and the whole energy
range the coefficients agree within 10%.
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